눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.
P310
즉시 의료기관(의사)의 진찰을 받으시오.
삼켰다면 즉시 의료기관(의사)의 도움을 받으시오.
P330
입을 씻어내시오.
P332+P313
피부 자극이 생기면 의학적인 조치· 조언을 구하시오.
P362
오염된 의복을 벗고 세척 후에 재사용하기
P370+P378
화재 시 불을 끄기 위해 (Section 5. 폭발, 화재시 대처방법의 적절한 소화제)을(를) 사용하시오.
P403+P233
용기는 환기가 잘 되는 곳에 단단히 밀폐하여 저장하시오.
P403+P235
환기가 잘 되는 곳에 보관하고 저온으로 유지하시오.
P405
밀봉하여 저장하시오.
P501
...에 내용물 / 용기를 폐기 하시오.
NFPA 704
0
2
0
반데타닙 C화학적 특성, 용도, 생산
개요
In April 2011, the U.S. FDA approved vandetanib (ZD6474) for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in adult patients with inoperable advanced ormetastatic disease. Vandetanib inhibits KDR/VEGFR2, VEGFR3, EGFR, and RET kinases with IC50's of 40, 110, 500, and <100 nM, respectively. In athymic mice bearing MTC tumors, a 14.5-fold reduction of tumor volume was observed after 45 days of treatment with vandetanib at 50 mg/kg/day. The decrease in tumor volume was accompanied by decreases in mitotic index (Ki67) and tumor angiogenesis in treated xenografts. Key steps in the synthesis of vandetanib include the displacement of the chlorine atom from 7-benzyloxy-4-chloro-6-methoxyquinazoline with 4-bromo-2- fluoroaniline under acidic conditions in a protic solvent and a Mitsunobu reaction of a N-protected piperidine alcohol with a phenol.
화학적 성질
Yellow Solid
용도
Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor kinase activity. The activity of Vandetanib plus Docetaxel was assessed
in patients with previously treated non-small-cell lung cancer (NSCLC).
Clinical Use
Vandetanib, an oral VEGF, EGF, and RET receptor tyrosine kinase
inhibitor, was developed by AstraZeneca for the treatment of
symptomatic or aggressive medullary thyroid cancer (MTC) in patients
with advanced or metastatic disease. This is the first drug
approved for the treatment of MTC. Trials for other cancer indications
such as small-cell lung cancer (SCLC), breast cancer, head and
neck cancer, colorectal cancer, hormone-resistant prostate cancer,
and papillary thyroid cancer are currently being explored. While
AstraZeneca had previously developed ZD-4190 which displays
similar efficacy and pharmacokinetic profile to vandetanib, vandetanib
exhibited significantly improved solubility.